Clinical trials: Lymphomas,
Relapsed or Refractory Hematologic Malignancies, Leukemia
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between…
- Conditions
- Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
- Trial name
- NCT07107204
- Testing
- BT02
- Volunteers
- 116 people
- Sponsor
- Biotroy Therapeutics
Cutaneous T-cell Lymphoma
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).
- Trial name
- NCT05296304
- Testing
- Bexarotene, Total Skin Electron Beam (TSEB)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DLBCL, MYD88 Gene Mutation
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.
- Conditions
- DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation, CD79B Gene Mutation
- Trial name
- NCT04994626
- Testing
- Ibrutinib Combined With Rituximab
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to…
- Trial name
- NCT04134325
- Testing
- Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Primary Mediastinal Large B Cell Lymphoma
A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment
The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)
- Trial name
- NCT06412068
- Testing
- Combined anti-PD-1 and R-CHOP
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin…
- Trial name
- NCT02134262
- Testing
- Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Jichi Medical University
B-Cell Acute Lymphoblastic Leukemia
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT07429461
- Testing
- SYNCAR-100 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Lymphoma
Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction Chemotherapy
This is a compassionate use protocol for participants who failed induction chemotherapy + Vaccine on previous trials. These participants then went on to high dose BEAM chemotherapy and transplant, then received idiotype vaccine…
- Trial name
- NCT00574886
- Testing
- Id-KLH
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Mantle Cell Lymphoma
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a…
- Trial name
- NCT03623373
- Testing
- Bendamustine, Rituximab, Acalabrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
CD20 Positive Non Hodgkin Lymphoma
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other…
- Trial name
- NCT04853329
- Testing
- CPO107
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
DLBCL - Diffuse Large B Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory…
- Trial name
- NCT07570823
- Testing
- SCTB35 injection, Rituxumab, Gemcitabine
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sinocelltech Ltd.
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Hodgkin Lymphoma
IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
The aim of study is to prove IGEV regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed Hodgkin lymphoma is effective.
- Trial name
- NCT01333605
- Testing
- IGEV
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Non-Hodgkin's Lymphoma
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
- Trial name
- NCT00582166
- Testing
- Ibritumomab Tiuxetan (Zevalin) + Rituximab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Lymphoma Leukemia
To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames
Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours
- Trial name
- Doxil (NCT03975205)
- Testing
- Doxorubicin
- Where
- India
- Volunteers
- 500 people
- Sponsor
- Sutphin Drugs
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06479356
- Testing
- Relma-cel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Bendamustine, Conditioning Therapy
Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).
The purpose of this study is to determine whether Bendamustine in combination with Etoposide, Cytarabine and Melphalan (BeEAM) are effective as conditioning followed by ASCT in patients with aggressive lymphoma.
- Conditions
- Bendamustine, Conditioning Therapy, Autologous Stem Cell Transplant, Aggressive Non Hodgkin's Lymphoma
- Trial name
- BeEAM2010-01 (NCT01296256)
- Testing
- Bendamustine-EAM
- Where
- 21 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination works in treating patients with B-cell non-Hodgkin lymphoma that has…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT02281279
- Testing
- rituximab, lenalidomide, romidepsin
- Sponsor
- Mayo Clinic
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy…
- Conditions
- AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Trial name
- NCT01193842
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 35 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.